Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine plus PENG block vs opioid plus PENG block in elderly diabetic patients undergoing total hip arthroplasty
ChiCTR2600116942Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Shanxi Medical University
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in post-operative cognitive decline (POCD) and postoperative pain (2 arms), sponsored by The Second Hospital of Shanxi Medical University. Primary endpoint: Montreal Cognitive Assessment (MoCA) score at 24 hours after surgery. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
post-operative cognitive decline (POCD)postoperative pain
Beyond the preview
Go deeper on ChiCTR2600116942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116942.